middle.news
Cynata Advances with Positive Diabetic Foot Ulcer Trial and $10.5m Cash Buffer
8:52am on Thursday 30th of January, 2025 AEDT
•
Biotechnology
Read Story
Cynata Advances with Positive Diabetic Foot Ulcer Trial and $10.5m Cash Buffer
8:52am on Thursday 30th of January, 2025 AEDT
Key Points
Phase 1 trial for CYP-006TK in diabetic foot ulcers completed with positive safety and efficacy
Phase 2 aGvHD trial recruitment surpasses 40%, with results expected late 2025
First patient treated in Phase 1 kidney transplant trial, cohort completion anticipated Q1 2025
Phase 3 osteoarthritis trial recruitment complete, results due first half 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE